In late June 2026, Labcorp highlighted new peer-reviewed evidence supporting its MVX and NIS2+ blood tests for assessing metabolic liver disease risk and announced nationwide U.S. launch of ColoSense,...
Source LinkIn late June 2026, Labcorp highlighted new peer-reviewed evidence supporting its MVX and NIS2+ blood tests for assessing metabolic liver disease risk and announced nationwide U.S. launch of ColoSense,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.